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Introduction 
 Picture this:  someone buys the stock of a firm that is about to announce the results of a 
drug’s FDA clinical trial the next day.  They go to bed that night, imagining the potential of their 
newly owned business to finally cure a disease that has impacted so many families.  They wake 
up the next morning to find that the firm has lost half of its market value because the drug failed.  
This is the stark reality that many small investors face:  the unpredictability of price movements 
in response to nonfinancial information being released to the public. 
In this thesis, I will examine the effects of FDA clinical trial announcements on the stock 
prices of small capitalization biotechnology stocks.  Literature has shown that markets can 
overreact to releases of information (DeBondt & Thaler, 1985; Fischer, 2012), but that negative 
information releases garner a greater magnitude of overreaction and correction than their positive 
counterparts (Atkins & Dyl, 1990).  These effects are important for us to understand because of 
the massive shifts in stock price that are caused by these test results, no matter the level of 
materiality.  In addition, biotech stocks are especially susceptible to market overreaction (Golec 
& Vernon, 2009), and their FDA announcements are critical in their valuation (Fan, 2010).  This 
study will contribute to the literature on investor irrationality by examining market overreaction 
to FDA clinical trial announcements.  
I focus on small cap biotech stocks in this study because they are especially susceptible to 
wild swings in stock price.  Being a small cap firm does not necessarily mean that the stock price 
is low, but low-priced biotech firms tend to be of a small capitalization.  That being said, the 
trading of these firms takes place in a much different setting than their larger counterparts.  
Plenty of smaller investors rely on biotech firms for capital gains.  To benefit these investors and 
the biotech firms themselves, research has been conducted to determine if the market overreacts 
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to FDA clinical trial announcements and subsequently corrects in the days after for small cap 
biotechnology stocks.  In addition, the relationship between positive or negative news and the 
subsequent price movement is thoroughly explored, and possible explanations for investor 
behavior are examined. 
Previous studies on investor attention find that increased investor attention has a 
significant impact on stock price movements (Chen, 2019; Gervais et al., 2001), with this effect 
concentrating on smaller and less visible stocks.  Because small biotech companies are less 
visible relative to larger companies, increases in investor attention should theoretically have a 
significant impact on small biotech firms’ stock price.  I investigate the possible effects of 
increased investor attention on market overreaction to FDA clinical trial announcements.  
Following the literature, the increase in investor attention is depicted by the increase in trading 
volume relative to the stock’s average trading volume in the period immediately before the 
announcements.   
In this study, I employ a sample of 78 announcements released by 50 different small cap 
biotech companies in the period from January 2011 to October 2018.  I classify announcements 
as positive if the firm’s tested drug has passed Phase I, II, or III, or has been approved for 
deployment in Phase IV.  I classify announcements as negative if the firm’s drug has failed any 
phase or is discontinued for any reason.  I measure market reaction to those announcements with 
buy-and-hold returns over 1-day, 2-day, and 5-day windows immediately following the 
announcements.   
This study finds that the market does not overreact to positive announcements of FDA 
clinical trial results, but overreacts to negative announcements.  The empirical results show that 
1-day and 5-day buy-and-hold returns are negatively related to returns on days of negative 
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announcement, indicating market overreaction on announcements and subsequent correction.  
This relationship does not hold for positive announcements.  This is consistent with the findings 
in the previous literature that negative overreaction was more significant than positive 
overreaction.  In addition, the empirical results show that increased investor attention significant 
impacts subsequent corrections for negative announcements.  With increased investor attention, 
1-day and 5-day buy-and-hold returns are 8.30% and 15.85% lower, respectively.  This is 
consistent with the findings in Chen (2019) where increased investor attention helps spread the 
news, reducing information asymmetry among investors.  However, this relationship does not 
hold for positive results. 
 
Definitions 
 For the purposes of this study, the term “small cap” refers to a firm with a total market 
value of less than $2 billion.  Small cap stocks can often be found in a state of financial struggle.  
Hence, the stock prices of these firms can be low because of the dire financial straits of the 
companies, though this is not always true.  Small cap firms are much more volatile than larger 
firms for a variety of reasons:  intense speculation, number of shares available, and large 
percentage of shares sold short, to name a few. 
 Biotechnology is the use of biological means for the production of antibiotics, hormones, 
and other medicinal products.  A publicly-traded biotechnology firm relies on the production of 
drugs and subsequent sale to conduct business.  Thus, many biotech firms have net losses in their 
first several years in operation.  However, if drugs pass all required tests and make it to the 
market, they have huge potential because they are often for conditions that do not have a current 
treatment or whose treatment is astronomically expensive. 
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 Market overreaction is the mispricing of a security because of a news announcement.  
One explanation for this phenomenon is investors’ desire to ride the initial wave of the stock 
price.  Subsequently, a stock price that shows evidence of overreaction will correct in time 
afterwards.  Thus, the subsequent correction in stock price shows that the overreaction was 
present in the first place.  The theory of market overreaction contends that investors respond too 
strongly to the initial announcement, causing a sizable price change in a direction determined by 
the announcement.  In theory, this price change causes a discrepancy between the intrinsic value 
and the stock price.  For market overreaction to be evident, this discrepancy between intrinsic 
value and price will be corrected in a period of time following the initial reaction.   
 Buy-and-hold return, or BHR, is the return of a stock when it is bought and held for a 
specific period of time.  On the other hand, abnormal return is the return achieved by a stock that 
is different from the expected rate of return.  In this case, the expected rate of return is the return 
of a market index.  Abnormal return gives a better idea of the effect of firm-specific news on the 
stock price of a firm because it accounts for the direction of the market in the time period used. 
 
Literature Review 
 To examine the background of the market surrounding this study, a thorough analysis of 
existing literature must be conducted.  In this manner, I observe the evidence of market 
overreaction that has stood the test time.  Second, I consider information about investor attention 
and the effects of its increase on stocks.  Lastly, I delve into the uniqueness of biotech stocks and 
what makes them different from others.  This information should afford the reader a greater 
understanding of the topics at hand and how they relate to biotech stocks and FDA clinical trial 
announcements. 
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Market Overreaction 
 According to the NASDAQ, the overreaction hypothesis is “the supposition that investors 
overreact to unanticipated news, resulting in exaggerated movements in stock prices followed by 
corrections.”  In line with this theory, stocks that have large movements in price have been 
shown to reverse those movements as time passes.  DeBondt and Thaler (1985) found that 
“consistent with the predictions of the overreaction hypothesis, portfolios of prior ‘losers’ are 
found to outperform prior ‘winners’” (p. 804).  This study shows that stocks with large initial 
decreases in price generated much higher returns over time than those with large initial increases.   
After large changes, the stock price will eventually return to the intrinsic value of the firm as 
perceived by investors.   
 Other studies have come to similar conclusions as to DeBondt and Thaler.  Howe (1986) 
found that “stocks that experienced large positive returns (good news) performed poorly in the 
50-week period following that event, with returns averaging about 30% below the market” (p. 
76).  The same pattern can found in numerous times in history, whether that be the tulip bulb 
craze in the Netherlands, or the credit bubble of 2008.  Prices will go up or down, and many 
investors will mistakenly think that they will keep in the same direction forever.  As always, the 
price falls and leaves many investors holding the bag.   
Not surprisingly, market overreaction is well documented in the pharmaceutical industry.  
Fischer (2012) observed that “investors overreacted to product news but then preceded to 
‘overcorrect’ their initial overreaction” (p. 88).  However, this type of correction to the initial 
price movement is common throughout the market.  Chen (2019) found that daily winner and 
loser stocks are followed by immediate price reversals, and increased investor attention, proxied 
by positive volume shocks, increases buy-and-hold returns of daily winner and loser stocks in the 
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following period.  This means that not only is the market overreaction hypothesis documented in 
the long-term time horizon, but also in the short-term. 
 For positive announcements, especially in the market for small cap stocks, short-selling 
can play a major factor in the following days’ price movements.  Diether et. al (2009) found that 
“short sellers in both NYSE and Nasdaq stocks increase their short-selling activity after periods 
of positive returns, on days with significant buying pressure, and on days with high levels of 
asymmetric information” (p. 604).  The authors also note that a strategy of said short-sellers is 
based on short-term market overreaction.  In addition, they observed “[short sellers’] trades 
correspond to 31% and 24% of share volume on Nasdaq and the NYSE, respectively. This 
suggests that the costs of borrowing stocks for short sales are not constraining US short sellers 
significantly” (p. 604).  This is significant for biotech stocks and especially for those with small 
market capitalizations because of their hard-to-borrow rates.  This rate is the annual interest rate 
that a short seller is subject to upon borrowing a share with the intent to sell.  For small cap 
stocks, this rate is typically very high.  So, investors do not care much about the interest rate they 
pay for shorting a small cap stock because it is likely a short-term position. 
In addition to positive news garnering an overreaction from the market, other studies 
have pointed out that negative overreactions are just as if not more common than positive 
overreactions.  Atkins and Dyl (1990) observed this in their study of NYSE stocks from 1975 to 
1984: 
We find that stocks that exhibit a large price decline (losers) subsequently earn 
significant abnormal returns.  Our interpretation is that the initial price change was an 
overreaction.  We also find evidence that stocks that exhibit a large price increase 
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(winners) subsequently earn negative abnormal returns, but that the magnitude of the 
overreaction is much smaller for winners (p. 546). 
These findings have large implications for small cap biotech firms.  If it applies, it would mean 
that firms that announce negative clinical trial results would gain some value back in the days 
following the announcement.  On the other hand, positive announcements would still produce  
overreactions, but to a lesser extent, thus making the price movement more permanent. 
 
The Attention Effect 
 There exists in the stock market a concept of investor attention, the level of which is 
interpreted by the trading volume of a stock.  The amount of trading volume for a particular 
stock can greatly affect the price of that stock.  As Gervais et al. (2001) found, “Periods of 
extremely high volume tend to be followed by positive excess returns, whereas periods of 
extremely low volume tend to be followed by negative excess returns” (p. 915). Thus, the 
periods of high volume that tend to correspond with important announcements like FDA clinical 
trial results should be expected to push the stock price higher than normal, as long as the 
announcement provides good news.  On the other hand, the negative excess returns would occur 
when trading volume is well below its average for the stock, as most of the trading done when 
volume is low is selling.  In addition, Chen (2019) found that “with a positive volume shock, 
extreme daily returns are positively related to subsequent [buy-and-hold returns] of daily winner 
and loser stocks, leading to economically less significant price reversals for both daily winner 
stocks and daily loser stocks” (p. 24).  By and large, extreme trading volume can have a huge 
impact on the price movement of stocks. 
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The Biotech Difference 
 Biotechnology firms are especially susceptible to investor overreaction because they have 
few drugs under their umbrella and are naturally volatile due to their size.  Golec and Vernon 
(2009) explain that “compared with pharmaceutical firms, biotech firms have even higher 
financial risks and are even more vulnerable to policy shocks” (p. 164).  Pharmaceutical firms 
can typically finance the development of new drugs with debt or earnings from established 
drugs, whereas biotechnology firms are limited to financing research and development with 
external equity.  Thus, when short on cash, biotech firms will have to issue shares, thereby 
diluting their stock price.  Their limited access to capital makes them more reliant on the success 
of their drugs.  This results in more volatility around FDA clinical trial announcements. 
 Because of limited financing opportunities, biotech companies can have plenty of trouble 
in getting their drugs through FDA trials.  Delays, setbacks, and outright failures are common 
with small biotech firms.  Czerepak and Ryser (2008) found in their study that of the firms that 
had drug failures in Phase III, most (95%) were biotech companies.  In addition they found that 
many drugs from biotech firms suffered three-month delays and other serious setbacks, such as 
poor-quality NDA (New Drug Application) submissions.  Setbacks and delays could seriously 
impact the price of a biotech firm whose value relies solely on its few drugs. 
 Announcements like the setbacks, failures, and approvals are shown to have an impact of 
the stock prices of the respective biotech firms.  Fan (2010) found that “the evidence proves that 
the announcements are likely significantly determining reasons for the particular actions” (p. 30-
31).   The impact of these announcements may be determined by investor behavior, but it is not 
only felt by investors.  These announcements can have serious effects on the valuation of the 
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firm, and those effects are often felt within the company.  In Dobson’s (2000) article, one biotech 
executive put it like this after a 67% dive in their stock price: 
It is a very unforgiving environment.  The downside is the vast swings in fortunes 
it can engender.  We lost two thirds of our share price, but only one out of seven 
products in the clinic.  That seemed to us to be a vast overreaction.  We were 
hammered (p. 1039). 
While these announcements are known to have serious consequences for the stock prices of 
biotech firms, the extent of their impact is largely unknown.  The purpose of this paper is to find 
the extent to which these announcements affect stock prices. 
 
Hypothesis 
 The literature discussed shows that announcements have an impact on biotech firms’ 
valuation (Fan, 2010) and that biotech companies are especially susceptible to market 
overreaction (Golec & Vernon, 2009).  In addition, there is a large amount of evidence in support 
of the concept of market overreaction (DeBondt & Thaler, 1985; Fischer, 2012; Chen, 2019).  
Based on this literature, the FDA clinical trial announcements should have a significant impact 
on the stock prices of the firms studied.  In the days to follow, stock prices should move 
significantly in the opposite direction compared to the announcement day. This movement will 
illustrate an overreaction to the news by investors on announcement days.  However, for positive 
announcements, the overreaction will not be as definitive as that for negative announcements, as 
prior studies (Atkins & Dyl, 1990) have shown that positive announcements do not produce as 
large an overreaction as negative announcements.  Therefore, I test the following two hypotheses 
in this study: 
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 H1: Subsequent correction for positive announcements is statistically insignificant. 
 H2: Subsequent correction for negative announcements is statistically significant. 
 
 In addition, based on the literature on investor attention, an increase in trading volume 
and therefore investor attention should have a significant impact on stock returns following the 
announcement day.  However, knowing that positive announcements are likely to show less 
significance in terms of market overreaction, this statement may only prove to be true for stocks 
with negative announcements.  Therefore, I test the following two hypotheses for the impact of 
increased investor attention. 
 
H3: Increased investor attention has no significant impact on market overreaction for 
positive announcements. 
H4: Increased investor attention has a significant impact on market overreaction for 
negative announcements. 
 
Methodology 
 Research was conducted on this topic throughout 2018, as many drugs had results of 
clinical trials coming in during the later months of the year.  The research involved gathering 
daily return data on many biotechnology firms, finding dates when announcements concerning 
FDA clinical trials were released, and corroborating the two to evaluate the effects.  An 
announcement was labeled as positive if the firm’s tested drug passed Phase I, II, or III, or was 
approved for deployment in Phase IV.  Announcements were classified as negative if the firm’s 
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drug failed any phase or was discontinued for any reason.   An event study was conducted to 
assess the impact of FDA clinical trial announcements on the stock prices of small cap 
biotechnology firms.   
 The whole data set gathered included 78 announcements from many different 
biotechnology firms and the returns of their respective stocks from three days prior to the 
announcement date to ten days after.  The S&P 500 returns for the same three days prior and ten 
days after the announcement date were also gathered for the purposes of this study.  In addition 
to returns, other important financial information was gathered on the companies represented in 
the study.  This information included market capitalization at the time of announcement, trading 
volume and daily trading volume for the previous 30 days, firm betas, and book values per share 
for each company.  This data was necessary to determine if the nature of the market around of 
the time of announcements.  However, more analysis of the data was required to determine the 
existence and/or extent of market overreaction and subsequent correction, so an event study was 
conducted. 
 The event study was used to determine the significance of several variables in regards to 
the return on the stock in the days following the announcement.  The variables used were the 
return on Day 0, market return on Day 0, natural log of market capitalization, market-to-book 
ratio, beta, and volume shock.  These variables were determined specifically for this case of 
small cap biotech stocks as the most critical pertaining to returns on stock price.  To examine the 
relationships between the aforementioned variables and returns in the days following 
announcement, linear regressions were used.  The returns for Day 1, Days 1 through 2, and Days 
1 through 5 were used to represent the returns in the days following an announcement.  These 
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returns were used to investigate possible correction in stock price in response to a market 
overreaction immediately after an announcement. 
 Day 0 return was used to represent the return immediately following an FDA clinical trial 
announcement.  This factor is one of the central determinants of market overreaction in response 
to announcements, as the movement of the stock price shows the reaction of investors to 
whatever happened that day or the day before.  This return was calculated as the difference in 
closing prices between Day 0 and Day -1 divided by the closing price on Day -1.   
 Another variable used in the regressions was the market return on Day 0.  This was used 
to factor in the direction of the price movement in the stock market as a whole, as many firms’ 
stock prices are dependent on the action in the broader market.  The market return is usually a 
base for which the firm to build upon in regards to daily return.  This is because of the 
differentiation between market and firm-specific risk.  Market risk describes that which is not 
able to be eliminated through differentiation.  Firm-specific risk, as its name implies, applies 
only to the firm and its own financial risks.  The inclusion of market return in the analysis allows 
for the observation of the return achieved by the firm in excess of the market, or abnormal return. 
 In addition, the market capitalization of each firm at the time of announcement was 
included in the analysis.  A firm’s size is an important factor in the movement of its price, as the 
number of shares outstanding (a factor of market capitalization) determines in part the supply 
side of the stock.  Thus, stocks with fewer shares outstanding are more volatile, meaning that 
they are susceptible to large movements in price.  This volatility is often the case for many 
biotech stocks.  So, in theory, small market capitalizations in biotech stocks should result in more 
volatility around the time of announcements. 
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 Another variable used in the regressions that also relates to volatility is a firm’s beta.  
This is the correlation between the firm’s returns and the market as a whole over the previous 
three months.  Using beta in the analysis helps to pinpoint the movement in price that is caused 
by the market and that which is caused by the firm, although it is much more of a long-term 
measure than short-term.  This is also accomplished because beta is a measure of volatility for 
the individual stock in respect to the market as a whole. 
 To analyze the possibility of market overreaction and subsequent correction in the sample 
of biotech stocks, the following Ordinary Least Squares regression model was used: 
 
BHRn  = β0 + β1Returnn + β2MktReturn + β3Sizen + β4Betan + β5VolumeShockn + β6MTBn 
 
BHRn is the buy-and-hold return for stock n for the 1-day, 2-day, and 5-day return periods after 
announcement.  Returnn is the return of stock n on Day 0, which is the first day on which 
investors are trading on the news of the announcement.  MktReturn is the return of the S&P 500 
on Day 0.  Sizen depicts the natural logarithm of the market capitalization of firm n on Day 0.  
Betan refers to the beta of firm n on Day 0.   VolumeShockn is an indicator variable that is equal 
to one if trading volume on Day 0 exceeded the daily trading volume of the previous 30 trading 
days and is equal to zero otherwise.  Lastly, MTBn, refers to the market-to-book ratio of stock n 
on Day -1, the day prior to the announcement.   
 
Results 
Table 1 (see Appendix) shows how skewed the summary statistics are toward the 
characteristics of negative announcements.  Despite only two more negative announcements than 
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positive, the sample has a mean Day 0 return of -13.44% as seen in Table 1.  Table 2 shows how 
little impact the positive announcements in the sample affected investors’ perception of the 
companies, as the median Day 0 return is 1.39%.  On the other hand, Table 3 shows how 
negatively investors reacted to announcements of the same manner.  The median return on Day 0 
for negative announcements is -23.31%. 
Through analysis of the regression results, it can be determined that for FDA clinical 
trials of small cap biotech companies, the market overreacts and subsequently corrects for 
negative announcements, but does not do so for positive announcements.  The evidence for this 
is shown in Tables 4, 5, and 6, where there are several variables that are shown to be significant 
for negative announcements.  There are a few sporadic variables that are significant for all 
announcements, but none for positive announcements.   
By looking at the regression results in Table 4, it is observable that there are no 
significant variables for the positive FDA clinical trial announcements.  This means that in the 
sample for this study, there is no evidence of overreaction or subsequent correction to positive 
announcements.  In addition, volume shock is not significant for positive announcements.  
Looking at negative announcements, Table 5 shows several significant variables in the analysis.  
Stock returns on the announcement day are negatively related to 1-day buy-and-hold returns, 
significant at the 10% level.  This indicates market overreaction on the announcement day and 
subsequent correction. Volume shock is significant for negative announcements.  From this, it 
can be interpreted that market overreaction and subsequent reaction exists in the sample of stocks 
with negative announcements.  The regression results show that the market does not overreact to 
positive announcements but overreacts to negative announcements.  Therefore, we accept both 
hypotheses 1 and 2 in regard to market overreaction.  However, the results support the second 
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hypothesis proposed earlier in this paper, as market overreaction for negative announcements is 
far greater than that for positive announcements.  This is consistent with literature previously 
discussed in this paper (Atkins and Dyl, 1990).  However, this is because no statistically 
significant overreaction takes place in the positive category.  Investor attention is also shown to 
be significant for negative announcements but insignificant for positive announcements.  Thus, 
we also accept hypotheses 3 and 4 in regard to investor attention and volume shock. 
The market overreaction and subsequent correction for negative announcements is most 
evident in 1-day and 5-day returns after the announcement.  Both of these intervals have five 
variables that have been deemed statistically significant by the linear regressions.  Of course, all 
three intervals for negative announcements show evidence of market overreaction and 
subsequent correction, but these two are the most significant.  This would suggest that stock 
price movements from negative announcements take a day or several trading days to gradually 
revert back to the previous price, although most never reverse that far. 
The differences in reaction to announcements are easily observed when looking at the 
summary statistics in Table 3.  The mean Returnn for negative announcements of -32.04% is far 
greater a reaction than that for positive announcements of 6.14%.  This could be for a variety of 
reasons.  For one, the market could be slower to react to positive announcements than to negative 
announcements.  The urge to sell on negative news could outweigh the urge to buy on positive 
news.  This could also be caused by the positive news already being priced in.  If true, investors 
would already believe the drug to be a future success, thus minimizing the impact of a positive 
announcement on the stock price.  In addition, negative announcements were much more 
susceptible to extreme movements in price on the day following announcement.  The 25th 
percentile for negative announcements found in Table 1 is -63.81%.  This number is in stark 
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contrast with the same variable for positive announcements, which equals -2.69%.  The fact that 
at least 25% of Day 0 returns after positive announcements were negative is actually quite 
surprising.  It shows just how indifferent investors are to positive announcements in comparison 
to negative announcements.  Or, it could show that the guidance provided in the announcements 
or their tone could be impacting the returns of the following day.  Unfortunately, these factors 
are beyond the scope of this study. 
 
Conclusion 
 Small cap biotech stocks are susceptible to large movements in stock price.  There is a 
plethora of smaller investors that rely on biotech firms for capital gains.  The prices of biotech 
are largely (although temporarily) dependent on the results of their FDA clinical trials on drugs 
that they are trying to bring to market.  Literature also shows that the market overreacts to similar 
releases of information.  Therefore, there is utility in examining the effects of these 
announcements on the prices of small cap biotech stocks. 
In the study of small cap biotech stocks and their FDA clinical trial announcements from 
2011 to 2018, it is observable that the market overreacts to negative announcements but does not 
overreact to positive announcements on the days of their release.  There is also evidence of 
subsequent correction for negative announcements, but none for positive announcements.  This 
conclusion could be inferred just by looking at the summary data, as the initial return for 
negative announcements is massively negative while that for positive announcements is barely 
positive.   
Although no significant variables were found in the analysis of positive announcements, 
several were found for negative announcements.  For 1-day BHRs, these included Returnn, 
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MktReturn, Betan, VolumeShockn, and MTBn.  For 5-day BHRs, these included Sizen, Betan, 
VolumeShockn, and MTBn.  While the significant variables are not the same for each time interval 
after announcement, the mere presence of these significant variables provides evidence as to the 
theory of market overreaction and subsequent correction in small cap biotech stocks. 
Of course, this study had some limitations.  For one, it only expands on the behavior of 
small cap biotech stocks.  This only provides information about the most volatile of securities, so 
the passive or long-term investor gains no benefit.  Plus, a larger sample of announcements 
would have greatly contributed to the evidence.  However, I had to make do with the information 
that was available.  For many companies and drugs, there was not a great deal of information 
available.  This certainly hampered the data gathering process as well as the overall sample size. 
Despite these limitations, the evidence acquired in this study is significant to the field, as 
it gives us a glimpse into the behavior certain penny stocks.  This is particularly useful for 
investors who trade these securities, as they have been the bane of many investors’ existence.  
This study shows that there is a behavioral pattern within the movement of these securities.  
However, there is still plenty to learn about biotech stocks and the factors that affect their price.  
FDA clinical trial results are just one type of announcement that has this kind of impact.  If 
future research were to be conducted on small cap securities, I believe it should be about the 
impacts of earnings announcements.  There is evidence for the effects of earnings 
announcements for the market as a whole, but not specifically for small cap stocks.  It would be 
interesting to see if there is any difference between the total market and some of the most volatile 
stocks it contains.   
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Appendix 
Table 1.  Summary Statistics for All Announcements 
This table includes summary statistics for positive and negative announcements.  Returnn is the 
return of the stock on the day immediately following announcement.  MktReturn is the return of 
the market on the day immediately following announcement.  Sizen is the natural logarithm of the 
firm’s market capitalization at the time of announcement.  Betan is the firm’s correlation with the 
market at the time of announcement.  VolumeShockn is the value (0 or 1) that depicts whether the 
trading volume of the firm’s stock on Day 0 exceeds the daily trading volume of the previous 30 
days.  MTBn is the ratio of the firm’s stock price on Day -1 and book value per share at the same 
time. 
 
Variables Mean Median 25th 
Percentile 
75th 
Percentile 
Standard 
Deviation 
n 
Returnn -13.44% -2.63% -23.31% 2.98% 31.10% 78 
MktReturn 0.12% 0.17% -0.11% 0.53% 0.87% 78 
Sizen 20.22 20.21 19.63 20.93 0.92 78 
Betan 2.08 2.07 1.47 2.67 0.84 78 
VolumeShockn  0.88 1.00 1.00 1.00 0.32 78 
MTBn  -0.95 3.66 1.84 5.58 53.89 78 
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Table 2.  Summary Statistics for Positive Announcements 
This table includes summary statistics for positive announcements.  All variables are defined in 
Table 1. 
 
Variables Mean Median 25th 
Percentile 
75th 
Percentile 
Standard 
Deviation 
n 
Returnn  6.14% 1.39% -2.69% 10.17% 14.29% 38 
MktReturn  -0.06% 0.22% -0.26% 0.48% 1.11% 38 
Sizen  20.47 20.44 19.81 21.22 0.87 38 
Betan  2.11 2.08 1.57 2.56 0.88 38 
VolumeShockn  0.89 1.00 1.00 1.00 0.31 38 
MTBn  -6.46 4.11 2.42 8.14 76.83 38 
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Table 3.  Summary Statistics for Negative Announcements 
This table includes summary statistics for positive announcements.  All variables are defined in 
Table 1. 
 
Variables Mean Median 25th 
Percentile 
75th 
Percentile 
Standard 
Deviation 
n 
Returnn  -32.04% -23.31% -63.81% -1.07% 31.42% 40 
MktReturn  0.30% 0.11% -0.06% 0.61% 0.51% 40 
Sizen  19.97 20.11 19.44 20.34 0.91 40 
Betan  2.05 1.97 1.35 2.72 0.80 40 
VolumeShockn  0.88 1.00 1.00 1.00 0.33 40 
MTBn  4.28 2.91 1.80 4.84 8.73 40 
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Table 4. Market Correction after Positive Announcements 
This table includes the regression results for positive announcements.  All variables are defined 
in Table 1 above.  T-statistics are reported in italics.  Asterisks (*, **, ***) correspond with 
significance levels of 10%, 5%, and 1%, respectively.   
 
 1-Day BHR 2-Day BHR 5-Day BHR 
Returnn 0.0704 
0.8616 
0.0641 
0.5881 
0.2109 
1.5986 
MktReturn -1.1633 
-1.0925 
-0.1783 
-0.1254 
-1.2267 
-0.7134 
Sizen -0.0043 
-0.3589 
0.0048 
-0.2988 
0.0113 
0.5787 
Betan -0.0047 
-0.3352 
-0.0166 
-0.8863 
-0.0022 
-0.0948 
VolumeShockn -0.0226 
-0.6139 
-0.0314 
-0.6389 
-0.0475 
-0.7979 
MTBn -0.0001 
-0.8126 
-0.0003 
-1.6218 
-0.0002 
-0.8474 
Intercept 0.1159 
0.4627 
-0.0380 
-0.1137 
-0.1859 
-0.4594 
n 38 38 38 
R2 0.1057 0.1437 0.1328 
 
  
24 
 
Table 5. Market Correction after Negative Announcements 
This table includes the regression results for negative announcements.  All variables are defined 
in Table 1 above.  T-statistics are reported in italics.  Asterisks (*, **, ***) correspond with 
significance levels of 10%, 5%, and 1%, respectively.   
 
 1-Day BHR 2-Day BHR 5-Day BHR 
Returnn -0.1000* 
-1.9909 
-0.0448 
-0.7016 
-0.0452 
-0.5566 
MktReturn 7.0415** 
2.4869 
3.3629 
0.9344 
6.4108 
1.3986 
Sizen 0.0104 
0.6715 
0.0144 
0.7300 
0.0518** 
2.0605 
Betan -0.0563*** 
-3.2743 
-0.0504** 
-2.3058 
-0.0532* 
-1.9103 
VolumeShockn -0.0830* 
-1.7955 
-0.0790 
-1.3457 
-0.1585** 
-2.1197 
MTBn 0.0055*** 
3.1654 
0.0040 
1.8169 
0.0131*** 
4.6651 
Intercept -0.0999 
-0.3255 
-0.1725 
-0.4420 
-0.8752* 
-1.7609 
n 40 40 40 
R2 0.5022 0.2566 0.5574 
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Table 6. Market Correction after All Announcements 
This table includes the regression results for both positive and negative announcements.  All 
variables are defined in Table 1 above.  T-statistics are reported in italics.  Asterisks (*, **, ***) 
correspond with significance levels of 10%, 5%, and 1%, respectively.   
 
 1-Day BHR 2-Day BHR 5-Day BHR 
Returnn -0.0529 
-1.6548 
-0.0148 
-0.4066 
-0.0530 
-0.9725 
MktReturn 0.3429 
0.3012 
0.3540 
0.2733 
-0.0059 
-0.0030 
Sizen 0.0158 
1.4830 
0.0193 
1.5914 
0.0538*** 
2.9632 
Betan -0.0324*** 
-2.7165 
-0.0323** 
-2.3850 
-0.0239 
-1.1754 
VolumeShockn -0.0037 
-0.1199 
-0.0264 
-0.7538 
-0.0488 
-0.9307 
MTBn -0.0001 
-0.2811 
-0.0003 
-1.2191 
0.0000 
-0.0608 
Intercept -0.2567 
-1.1929 
-0.3082 
-1.2596 
-0.9949*** 
-2.7129 
n 78 78 78 
R2 0.1354 0.1209 0.1305 
 
